Navigation Links
Viral Genetics CEO Issues State of the Company Update
Date:2/11/2010

SAN MARINO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- (Pink Sheets: VRAL) -- Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

During 2009, Viral Genetics made significant strides on two fronts -- scientific and financial. Our drug compounds seem to be showing great potential. Additionally, we've built an infrastructure that enables us to use money wisely. We have retired nearly all of our external debt, enabling us to leverage any additional funding to advance new drug therapies -- rather than making interest payments to creditors.

Promising Drug Therapies

HIV/AIDS

Six international, human clinical trials found that our HIV/AIDS drug compound significantly reduced the viral load in some patients. That therapy led to the development of a second generation drug compound called VGV-X. We believe that VGV-X may address the reason that our first HIV/AIDS drug reduced the viral load in some patients, but not others. Preparing this therapeutic approach for human clinical trials will be a top priority during 2010.

Staph, Strep and Sepsis

Our new VGV-S drug compound has been found to provide an alternative to traditional antibiotics in laboratory animals infected with Staphylococcus or with high levels of Streptococcus. Testing during 2009 determined that some infected mice treated with VGV-S, made full recoveries. A control group of sick animals that weren't treated with this therapy either took much longer to recover or did not survive the infections.

The ani
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CDC Foundation Launches Viral Hepatitis Action Coalition
2. Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com
3. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
4. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
5. Noninvasive Breath Test Predicts Survival in Patients with Viral Hepatitis
6. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
7. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
8. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
9. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
10. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
11. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
(Date:7/10/2014)... Minn. The benefits of medical imaging far outweigh ... The Right Way, with The Right Radiation Dose. However, ... and Mayo Clinic is leading a collaborative effort to ... commentary, published online in the Journal of Patient ... the Joint Commission, the Intersociety Accreditation Commission, and the ...
(Date:7/10/2014)... at Rutgers University-Newark says the human brain operates much ... finding that could provide a better understanding of schizophrenia, ... afflict an estimated 13.6 million Americans. , In newly ... Cole, an assistant professor at the Center for Molecular ... of a person at rest is basically the same ...
(Date:7/10/2014)... Low-fat cheeses and cakes that are just as ... supermarket shelves, thanks to fresh insights into how ... and texture. , Funded by the Engineering ... at Heriot-Watt University and the University of Edinburgh ... into micro-particles and therefore closely mimic the behaviour ...
(Date:7/9/2014)... Cincinnati, OH, July 10, 2014 -- The World Health ... 60 minutes of moderate to vigorous physical activity (MVPA) ... most of their MVPA during school hours. Therefore, ... school hours would increase MVPA. In a new ... Pediatrics , researchers confirmed that time spent outdoors after ...
(Date:7/9/2014)... at the Perelman School of Medicine at the University ... Institute have received an $8 million grant from the ... photodynamic light therapy (PDT) in patients with malignant pleural ... often manifests itself in the lining of the lungs ... The grant will fund a clinical trial and additional ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Working to loosen the grip of severe mental illness 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2
... Calif., April 16 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, announced today ... company,s board of directors, effective May,31, 2008., ... LLC, has been a director,of Edwards since 2000, ...
... Wireless, the,builder and operator of the nation,s most ... mobile phone applications, today,announced the availability of The ... provides Verizon Wireless customers with detailed drug,information and ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080416/NYW008 ), The ...
... FRANCISCO, April 15 The Medical Tourism,Association, the ... tourism industry, announces the World Medical Tourism &,Global ... the,first medical tourism convention to take place in ... 9-12th, 2008 at the Westin St.,Francis in San ...
... owns your medical tests results and your personal health ... of personal liberty and freedom of information. Now, researchers ... Management have introduced the notion of ownership of medical ... adoption of personal health records. , Personal health records ...
... Most Promising ... of Technology, SUNNYVALE, Calif., April 16 Agito Networks, ... that it has been named a finalist for the Red ... based in North America., The Red Herring editorial board ...
... Publications LLC today,announced that its highly anticipated book ... will be released on April 28, 2008 in ... online book retailers,including Amazon.com., *(PHOTO 72dpi: ... Creating Your Dream Life.) An entirely new ...
Cached Medicine News:Health News:Edwards Lifesciences Announces Retirement of Director Vernon Loucks 2Health News:Verizon Wireless Customers Can Now Get Medication Information and Dosing Reminders with the Pill Phone Application on Their Phones 2Health News:Verizon Wireless Customers Can Now Get Medication Information and Dosing Reminders with the Pill Phone Application on Their Phones 3Health News:Medical Tourism Association Announces World's Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008 2Health News:Medical Tourism Association Announces World's Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008 3Health News:Breaking personal health records 2Health News:Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies 2Health News:Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies 3Health News:Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies 4Health News:21 Days to Creating Your Dream Life Will be Unleashed on April 28, 2008 2
... Flexible Cystoscope System using EndoSheath Technology ... for urologists in both their hospitals ... CST-2000 flexible cystoscope with the sterile, ... cystoscopy procedures, while minimizing the costs ...
... Super-Sect is a single-use device that ... minimal thermal spread and vapor sealing ... It can be used for resection ... tumor. It is also an excellent ...
... Cryocare® CS is a ... and treatment system designed ... allow unlimited flexibility. Cryocare ... meet specific physician needs ...
... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
Medicine Products: